We are live on ! Find out more
UBX

Unity Biotechnology
UBX

Delisted

UBX was delisted on the 8th of July, 2025.

Back to rankings

63 hedge funds and large institutions have $99.7M invested in Unity Biotechnology in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

9% more funds holding

Funds holding: 58 → 63 (+5)

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

0.08% less ownership

Funds ownership: 3.86% → 3.78% (-0.08%)

37% less capital invested

Capital invested by funds: $157M → $99.7M (-$57.8M)

Holders
63
Holders Change
+5
Holders Change %
+8.62%
% of All Funds
1.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
18
Reduced
18
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.46M
2
Millennium Management
Millennium Management
New York
+$1.31M
3
Citadel Advisors
Citadel Advisors
Florida
+$944K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$902K
5
OAM
Oxford Asset Management
United Kingdom
+$746K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$7.03M
2
Goldman Sachs
Goldman Sachs
New York
-$1.77M
3
SCM
Sio Capital Management
New York
-$956K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$455K
5
Morgan Stanley
Morgan Stanley
New York
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
51
Victory Capital Management
Texas
$21K +$24.6K +348 New
Bank of Montreal
52
Bank of Montreal
Ontario, Canada
$14K -$18.4K -260 -53%
AIP
53
Ameritas Investment Partners
Nebraska
$13K – – –
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$12K – – –
SO
55
STRS Ohio
Ohio
$9K – – –
AWM
56
AllSquare Wealth Management
New York
$3K – – –
GSWM
57
Golden State Wealth Management
California
$3K – – –
MAM
58
Meeder Asset Management
Ohio
$2K -$1.34K -19 -40%
Daiwa Securities Group
59
Daiwa Securities Group
Japan
$2K – – –
AG
60
Advisor Group
Arizona
$2K +$849 +12 +60%
IA
61
IFP Advisors
Florida
$2K +$2.12K +30 New
RE
62
RBC Europe
United Kingdom
$610 – – –
SCM
63
Sio Capital Management
New York
– -$956K -10,064 Closed
MIM
64
MetLife Investment Management
New Jersey
– -$140K -1,471 Closed
EMG
65
Ellington Management Group
Connecticut
– -$103K -1,080 Closed
AG
66
Aperio Group
California
– -$50K -527 Closed
MLICM
67
Metropolitan Life Insurance Company (MetLife)
New York
– -$22K -232 Closed
Group One Trading
68
Group One Trading
Illinois
– -$10K -110 Closed
1 2
3

UBX Hedge Fund Activity: Q3 2019 in Review

63 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2019, worth a combined $99.7M — down 37% from $157M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new UBX positions and 6 closed out — a net gain of 6 holders — while 18 added to existing stakes and 18 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.46M. The largest seller was EcoR1 Capital, cutting an estimated $7.03M.

  • 63 institutional investors held Unity Biotechnology (UBX) as of Q3 2019, up from 58 in Q2 2019.
  • Funds reported $99.7M of Unity Biotechnology stock for Q3 2019, down 37% quarter-over-quarter.
  • 12 funds opened new Unity Biotechnology positions in Q3 2019 and 6 closed out, a net change of +6 holders.
  • The largest Unity Biotechnology buyer in Q3 2019 was Vanguard Group, an estimated $2.46M added.
  • The largest Unity Biotechnology seller in Q3 2019 was EcoR1 Capital, an estimated $7.03M sold.

Based on aggregated 13F filings for Q3 2019.